Written by Jane Aubrey
The first week of August 2026 is shaping up to be a defining period for the biotechnology and pharmaceutical sectors, marked by a major label expansion in oncology and a looming, potentially historic decision in infectious disease prevention. The FDA’s recent approval of Novartis’s Pluvicto for an earlier stage of prostate cancer sets a new standard of care, while the industry collectively holds its breath for the August 5 PDUFA date regarding Moderna’s mRNA-based seasonal flu vaccine.
On July 31, the FDA granted approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This decision significantly broadens the eligible patient population for the targeted radioligand therapy, moving it earlier in the treatment paradigm. Previously, Pluvicto was approved only for patients with metastatic castration-resistant prostate cancer (mCRPC) who had already received androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy.
The approval for the mHSPC indication is based on the robust results of the Phase III PSMAddition trial. In this study, the addition of Pluvicto to standard ARPI and androgen deprivation therapy reduced the risk of radiographic progression or death by 33% compared to standard of care alone (HR 0.67; 95% CI: 0.55–0.82). While the overall survival (OS) data is not yet fully mature, the progression-free survival benefit was deemed sufficient for approval.
This expansion is strategically vital for Novartis. With PSMA expression present in over 80% of prostate cancer patients, the mHSPC indication effectively doubles the addressable market for Pluvicto. It positions the therapy as the only PSMA-targeted agent approved across the full metastatic spectrum, offering a critical new option for the approximately one-third of men who fail to achieve undetectable PSA levels on standard doublet therapy. However, oncologists will be closely monitoring the final OS readout from PSMAddition to fully validate the treatment’s long-term survival benefits against its toxicity profile.
Meanwhile, the spotlight shifts to Moderna, which faces a critical FDA decision on August 5 for its investigational mRNA-based seasonal influenza vaccine, mFLUSIVA (mRNA-1010). If approved, it would become the first seasonal flu shot in the United States utilizing mRNA technology, marking a massive milestone in validating the platform beyond COVID-19.
The anticipation surrounding the decision was heightened following Moderna’s Q2 earnings report on August 3. The company beat quarterly revenue estimates, reporting $145 million against expectations of $103 million, and posted a narrower-than-expected loss of $1.97 per share. Despite these beats, Moderna trimmed its full-year R&D expense forecast to $2.9 billion, down from $3.0 billion, citing the wind-down of several late-stage programs.
The FDA’s decision on mFLUSIVA is paramount for Moderna’s strategic pivot. Following a recent setback where its experimental norovirus vaccine missed an interim statistical benchmark, the company urgently needs a commercial victory to bolster its respiratory franchise. The vaccine recently received unanimous backing from the FDA’s Vaccines and Related Biological Products Advisory Committee, raising expectations for a positive outcome.
An approval on August 5 would not only validate Moderna’s pipeline but also potentially disrupt the established flu vaccine market, introducing the rapid adaptability and efficacy associated with mRNA technology to seasonal influenza prevention. As August unfolds, these regulatory milestones underscore a period of rapid advancement and high stakes in the biopharma landscape.
